ObjectiveTo systematically review the efficacy and safety of probiotics for the treatment of Helicobacter pylori (H.pylori) infection in children. MethodsWe electronically searched The Cochrane Library, PubMed, EMbase, CNKI, VIP and WanFang Data databases to collect randomized controlled trials (RCTs) about probiotics for the treatment of H.pylori infection in children from inception to January 2015. The references of included studies and conference proceedings were manually searched for additional studies. Two reviewers independently screened literature, extracted data and assessed the risk of bias of include studies. Then, meta-analysis was performed by using RevMan 5.3 software. ResultsA total of twelve RCTs were included, involving 1 227 patients. The result of meta-analysis showed that the probiotics adjuvant therapy group was superior to the control group in H.pylori eradication rates (OR=2.23, 95%CI 1.66 to 2.99, P<0.000 01) and the incidence of adverse effect (OR=0.31, 95%CI 0.18 to 0.53, P<0.000 1). ConclusionCurrent evidence shows that probiotics adjuvant therapy may be a new effective and safe solution in the treatment of H.pylori infections in children. Due to the limited quality and quantity of the included studies, more higher quality studies are needed to verify the above conclusion.
ObjectiveTo determine the expressions of Lgr5 protein and Ki-67 protein in gastric cancer tissues, and to analyze the possible function in the carcinogenesis and development of gastric cancer.MethodsThe SABC immunohistochemical method was adopted to examine the expressions of Lgr5 protein and Ki-67 protein in the 69 paraffin slices of gastric cancer from the patients, with the adjacent normal gastric tissue as the control group. The statistical relationship between the expressions of these two kinds of proteins and clinicopathologic features of gastric cancer was examined respectively.ResultsIn the gastric cancer tissue group, the expressions of Lgr5 protein and Ki-67 protein upregulated in comparison to the adjacent normal gastric tissue group [Lgr5 protein: 87.0% (60/69) versus 16.7% (5/30), χ2=45.81, P<0.001; Ki-67 protein: 79.7% (55/69) versus 36.7% (11/30), χ2=17.43, P<0.001]. The expressions of Lgr5 protein and Ki-67 protein all upregulated in the N1–N3 stage groups, lowly differentiated+undifferentiated groups and positive Helicobacter pylori (HP) groups. The expression of Lgr5 protein upregulated in the T3+T4 stage groups in comparison to T1+T2 stage groups, while, no significant relationship was found in the expression of Ki-67 protein and tumor T staging. No significant relationship was found between the gender or metastasis and the expression of these two proteins. There was a positive correlation between the Lgr5 protein expression and the Ki-67 protein expression in the gastric cancer (rs=0.340, P=0.004).ConclusionsIn the development progress of gastric cancer, the Lgr5 protein might get involved in the mechanism of tumor invasion, lymph nodal metastasis, and low differentiation. Ki-67 protein might get involved in the mechanism of lymph nodal metastasis and low differentiation. The two proteins, together with the HP infection, might play a synergistic role in tumorigenesis and development.
目的 幽门螺杆菌NCTC11637菌株Hp1501基因进行序列测定，并运用生物信息学软件对其进行分析。 方法 用聚合酶链反应方法从幽门螺杆菌 NCTC11637菌株基因组DNA扩增Hp1501基因，T-A克隆，鉴定后测序，将基因序列向GeneBank提交并申请登录号，用生物信息学软件分析其生物学特性。 结果 成功获取幽门螺杆菌 NCTC11637株Hp1501基因序列，获得GeneBank登录号JF820815。软件分析表明，序列全长为1 164 bp，与幽门螺杆菌国际标准株26695和J99的基因序列一致性为96%～97%，氨基酸序列一致性为97%～98%；软件预测其编码的前59个氨基酸为信号肽，其编码的核心肽为幽门螺杆菌外膜蛋白。 结论 成功测定幽门螺杆菌 NCTC11637菌株Hp1501基因序列并预测出其生物学特性，为进一步研究其功能，阐明其致病机制奠定了基础。Objective To determine the sequence of Hp1501 gene from H. pylori NCTC11637 and analyze the sequence with bioinformatics software. Methods Polymerase chain reaction (PCR) was used to amplify the Hp1501 gene from chromosomal DNA of H. pylori NCTC11637. After T-A clone, the amplified DNA sequence was determined and the gene sequence was sent to GeneBank for analysis with bioinformatics software. Results Hp1501 gene from H. pylori NCTC11637 was successfully attained, and the logging number for GeneBank was JF820815. The analysis showed that the gene sequence was 1164 bp in length, 96%-97% identical in DNA sequence and 97%-98% identical in amino acid sequence compared with standard strain 26695 and J99. The forward 59 amino acids were signal peptide and the core peptide was outer membrane protein of H. pylori based on the software prediction. Conclusions The sequence and bionomics of Hp1501 gene from H. pylori NCTC11637 has been determined successfully. It provides a solid base for the further research of the biological function and pathogenicity mechanism of H. pylori.
ObjectiveTo discuss the etiological factors and risk factors for peptic ulcer hemorrhage with negative Helicobacter pylori (HP). MethodsA total of 182 patients with peptic ulcer treated in our hospital from January 2010 to December 2012 were chosen in our study. There were 85 cases of hemorrhage among them, with 50 HP positive and 35 HP negative ones. The other 97 patients were without hemorrhage. Etiological factors and correlated risk factors for peptic ulcer hemorrhage with HP negative were analyzed. ResultsHP negative rate of the hemorrhage group was 41.2%, while that rate of the non-hemorrhage group was 14.4%, and the difference was significant (P<0.05). The patients with peptic ulcer hemorrhage with negative HP had correlations with age, sex, wine drinking, taking non-steroidal anti-inflammatory medicine and so on. ConclusionPeptic hemorrhage is easily complicated with peptic ulcer with negative HP, and it is intimately correlated with patients' age, sex, wine drinking history, and taking non-steroidal anti-inflammatory medicine, etc.
ObjectiveTo investigate the effect of sequential use of bifid triple viable in the eradication treatment of Helicobacter pylori (HP). MethodsA total of 183 HP positive chronic gastritis patients with gastric mucosa atrophy or erosion treated between October 2012 and October 2014 were randomly divided into three groups with 61 in each. The triple group received standard one-week triple therapy. The quadruple group received standard two-week quadruple therapy. The bifid triple viable group was given one week of standard quadruple therapy and one week of sequential bifid triple viable. One month after withdrawal of the medicine, HP eradication rate, clinical efficacy and adverse reactions were compared among the three groups. ResultsThe HP eradication rate in the triple group was 72.13%, significantly lower than that in the quadruple group (93.44%) and in the bifid triple viable group (90.16%) (P < 0.05). The HP eradication rate in the bifid triple viable group was slightly lower than that in the quadruple group (P > 0.05). The total effective rate in the quadruple group and bifid triple viable group was respectively 95.08% and 91.80%, with no significant difference between the two groups (P > 0.05), but they both were significantly higher than that in the bifid triple viable group (P < 0.05). Eleven cases of adverse reactions happened during the process of eradication treatment of HP. The adverse reactions were not serious, and could be solved with symptomatic treatments. The adverse reaction rate in the quadruple group was significantly higher than that in the bifid triple viable group (P < 0.05). ConclusionSequential use of bifid triple viable capsule can improve the rate of HP eradication, relieve the clinical symptoms effectively, reduce adverse reactions, and reduce the medical cost.
目的 探讨含左氧氟沙星的三联疗法作为一线方案对幽门螺杆菌感染治疗的有效性和安全性。 方法 选择2008年9月－2011年3月125例确诊为幽门螺杆菌感染的初治患者，随机分为雷贝拉唑、阿莫西林联合左氧氟沙星组（A组）和雷贝拉唑、阿莫西林联合克拉霉素组（B组），经治疗7 d后比较两组根除率和不良反应发生率。 结果 A、B组幽门螺杆菌符合方案分析根除率分别为91.8%、77.6%，意向性治疗根除率分别为88.9%、72.6%，A组根除率高于B组，差异有统计学意义（P＜0.05）。A、B组不良反应发生率分别为4.8%、3.2%（P＞0.05）。 结论 以左氧氟沙星、阿莫西林、雷贝拉唑为组合的三联疗法能显著提高幽门螺杆菌感染的初治成功率，不良反应少，安全有效。
Objective To evaluate the efficacy and safety of high-dose dual therapy (HDDT) in the treatment of Helicobacter pylori (HP) infection. Methods The clinical data of patients with HP infection who were treated in Suining Central Hospital between June 2020 and August 2021 were retrospectively collected. They were divided into HDDT group and bismuth-containing quadruple therapy (BQT) group according to the treatment regimen. The efficacy and adverse reactions of the two treatment regimens were observed. Results A total of 520 patients were included. Among them, there were 284 cases in the HDDT group and 236 cases in the BQT group. By propensity score matching, 223 pairs of patients were successfully matched. The eradication rates of HDDT and BQT were 74.4% and 77.1%, respectively (χ2=0.440, P=0.507), and the incidence of adverse reactions were 9.9% and 16.6%, respectively (χ2=4.395, P=0.036). Conclusion The efficacy of HDDT and BQT in the treatment of HP infection is comparable, but the former has fewer adverse reactions.
ObjectiveTo study the expression of cyclooxygenase2 (COX2) and its clinical significance in gastric carcinoma. MethodsThe expression of COX2 in 47 cases of gastric carcinoma and 16 cases of normal gastric tissue were detected by SP immunohistochemical technique. Helicobacter pylori (H.pylori) infection was diagnosed by urease experiment and Giemsa staining.ResultsThere was no positive signal of COX2 detected in normal gastric tissue. The positive expression rate of COX2 was 63.8%(30/47) in gastric carcinoma.The expression of COX2 was correlated with TNM stage, lymph node metastasis and H.pylori infection（P＜0.01）. Positive COX2 expression rate in H.pylori infection group was 72.4%(21/29), significantly higher than that in the group without H.pylori infection.Conclusion COX2 expression is involved in the carcinogenesis and malignant progression of gastric carcinoma.The examination of COX2 may be helpful to judge biological behavior of gastric carcinoma.